All differentiation markers (CYP3A4, HNF4α and albumin) in infigratinib‐treated FGFR‐dependent tumours were significantly increased compared with their levels in vehicle‐treated tumours (Figure 2A). This evidence concerns the gene CYP3A4 and neoplasm.